Form 10-Q Revance Therapeutics, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Revance Therapeutic (RVNC) PT Lowered to $31 at Stifel
November 10, 2021 6:49 AM ESTStifel analyst Annabel Samimy lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $31.00 (from $33.00) while maintaining a Buy rating.
The analyst commented, "RVNC reported solid revenues ($19.8mn/ Cons $20.3) from steady RHA-filler sales ($18.3mn) in a seasonally difficult quarter and meaningful expansion of... More
